Hematologic Malignancies Research News Updates
1 - 10 of 10
T-cell Therapy Pioneered at CHOP Shows Persistent Benefits in Young Leukemia Patients
Published on
Updated results from a global clinical trial of the CAR T-cell therapy for ALL reveal that children and young adults continued to show high rates of durable, complete remission of their disease.
Pediatric Immunotherapy: What’s Next for CAR-T Therapy
Published on
The FDA approval of Kymriah™ has shifted the paradigm for pediatric cancer treatment — and at Children's Hospital of Philadelphia, more cell therapies are on the horizon.
FDA Committee Recommends Approving First Cell Therapy to Successfully Treat Cancer
Published on
The experimental, personalized cell therapy that amps up the patient's own immune system has passed a critical milestone in the path to full FDA approval.
Research on Crucial Cutting Enzyme Maps DNA Damage in Leukemias
Published on
A DNA-cutting enzyme that regulates gene structure has a broad role in causing certain cancers. This discovery may eventually lead to more precise treatments.
New Developments in Precision Medicine Therapy for Children with Acute Lymphoblastic Leukemia
Published on
The Children’s Oncology Group (COG) high risk acute lymphoblastic leukemia (HR ALL) TARGET Project is a large collaborative effort led by Stephen Hunger, MD.
Younger T Cells May Improve Immunotherapy for Children’s Cancer
Published on
CHOP is working to improve personalized cell therapy for children. Using younger T cells may offer better results against certain types of leukemia and lymphoma.
Home or Away? Award to Study Post-chemo Recovery for Children with Leukemia
Published on
After children with leukemia receive chemotherapy, are they better off remaining in the hospital, or going home? CHOP is leading a multicenter study of both safety and family preferences.
Benefits Persist in T Cell Therapy for Children With Relapsed Leukemia
Published on
An innovative cell therapy against a highly aggressive form of acute lymphoblastic leukemia (ALL) continues to show highly promising results in children treated in a pilot study.
Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied
Published on
Ninety percent of children and adults with acute lymphoblastic leukemia (ALL) went into remission after receiving an investigational therapy, CTL019.
Cell Therapy for ALL Receives Breakthrough Therapy Designation
Published on
A personalized immunotherapy has been awarded the FDA's Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia.